Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Eli Lilly and Co Add to portfolio

INX:LLY, Feb 22, 03:16 UTC

Latest INX:LLY News

Filter your feed

Apply Filter

Yesterday


News

Comparing of GlaxoSmithKline plc (GSK) and Eli Lilly and Company (NYSE:LLY)

GSK LLY +1 more GSK LLY GSK

GlaxoSmithKline plc (NYSE:GSK) and Eli Lilly and Company (NYSE:LLY) compete with each other in the Drug Manufacturers – Major sector. We will analyze and compare their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation. GlaxoSmithKline plc is thus currently the affordable of the two stocks because it has a lower price-to-earnings ratio. The information presented earlier suggests that GlaxoSmithKline plc looks more robust than Eli Lilly and Company as far as analyst view.

Read Full Details

Story Sources

yomiblog.com
Topics:
  • Business
  • Health
  • Financial
News

Anti-tumor Drug Industry Outlook to 2023 – Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda, Eli Lilly, AstraZeneca, Astellas, Merck & Co, Sanofi, Bayer, Biogen Idec, Eisai, Teva, Otsuka – Honest Version

CELG SAN +10 more CELG SAN AMGN BAYN LLY JNJ PFE BMY AZN AZN BIIB MRK

Anti-tumor Drug Industry Outlook to 2023 – Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda, Eli Lilly, AstraZeneca, Astellas, Merck & Co, Sanofi, Bayer, Biogen Idec, Eisai, Teva, Otsuka. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. Such as Jiangsu Hengrui, Qilu Pharmaceutical and other well-known domestic enterprises in the anti-tumor drugs have invested a lot of money, there are many innovative anti-cancer drugs into the clinical research stage. In the meantime, there has been “explosive” growth in the development of molecularly targeted drugs, with at least hundreds of drugs under development, and it is conceivable that the market will be quite crowded in the next five to 10 years. Therefore, domestic enterprises should fully understand the feasibility of the project and the fierce market competition that they may face in the future.

Read Full Details

Story Sources

honestversion.com
Topics:
  • Business
  • Health
  • Science
News

Farmers & Merchants Investments Lifted Lilly Eli & Co (LLY) Position By $318,111; Broadway Financial (BYFC) Sentiment Is 9

LLY

Also, the number of investment managers holding Broadway Financial Corp in top ten positions was flat from 0 to 0 for the same number . Sold All: 0 Reduced: 1 Increased: 5 New Position: 4. It has outperformed by 32.86% the S&P500. Some Historical LLY News: 28/03/2018 – FDA: New Drug Application (NDA): 021253 Company: LILLY; 24/04/2018 – Eli Lilly Sees 2018 Effective Tax Rate About 17%; 20/03/2018 – CVS to Hire Former Eli Lilly CFO to Run Pharmacy Benefit Business; 03/04/2018 – Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America; 09/04/2018 – Merck’s Keytruda meets main goal in lung cancer trial; 14/05/2018 – Lilly to Buy Oncology Drug-Development Company AurKa — Deal Digest; 17/05/2018 – Oncolytics Biotech® Announces Collaboration with Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Ph; 20/04/2018 – Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer; 20/04/2018 – Lilly Previously Announced That Cyramza Trial Met Primary Endpoint of Investigator-Assisted Progression-Free Survival; 10/05/2018 – Eli Lilly Will Buy ARMO Biosciences For $1.6 Bln — MarketWatch. It also reduced Synchrony Financial (NYSE:SYF) stake by 46,619 shares and now owns 80,413 shares. $480,000 worth of Eli Lilly and Company (NYSE:LLY) shares were sold by Zulueta Alfonso G. $19.22 million worth of Eli Lilly and Company (NYSE:LLY) was sold by LILLY ENDOWMENT INC. O’Neill Myles had sold 25,000 shares worth $2.82 million on Monday, December 10.

Read Full Details

Story Sources

moveefy.com
Topics:
  • Business
  • Financial
News

4,934 Shares in Eli Lilly And Co (NYSE:LLY) Obtained by Diversified Trust Co – BharataPress

LLY

4,934 Shares in Eli Lilly And Co (NYSE:LLY) Obtained by Diversified Trust Co. Diversified Trust Co purchased a new position in shares of Eli Lilly And Co (NYSE:LLY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). Following the completion of the sale, the senior vice president now directly owns 26,562 shares of the company’s stock, valued at approximately $2,999,381.04. Shares of Eli Lilly And Co stock traded up $1.10 during trading hours on Thursday, hitting $120.75. BMO Capital Markets upped their price objective on shares of Eli Lilly And Co from $124.00 to $132.00 and gave the company an “outperform” rating in a research note on Monday, December 24th.

Read Full Details

Story Sources

bharatapress.com
Topics:
  • Business
  • Financial
News

Lookout For Analysts Forecast: Eli Lilly and Company (LLY), Barnes & Noble Education, Inc. (BNED)

LLY

Lookout For Analysts Forecast: Eli Lilly and Company (LLY), Barnes & Noble Education, Inc. (BNED). For Eli Lilly and Company (NYSE:LLY) Wednesday was another day of strong-handed buying, with the high volume day punctuated by a rise from previous close. Its shares recently got a closing price of $122.66 per share.Eli Lilly and Company (LLY): A 6% Rally In This Year — But Still Has Room To Fall -2.11%. According to 15 stock analysts, Eli Lilly and Company, is being kept at an average Outperform, rating, with at least 2.68% of shares outstanding that are currently legally short sold. With these types of results to display analysts, are more optimistic than before, leading 7 of analysts who cover Eli Lilly and Company (NYSE:LLY) advice their clients to include it in their buy candidate list. However, at the Wall Street, the shares for the company has been tagged a $120.07 price target, indicating that the shares will drop -2.11% from its current levels.

Read Full Details

Story Sources

postanalyst.com
Topics:
  • Business
  • Financial
News

GW Pharmaceuticals plc (GWPH) and Eli Lilly and Company (NYSE:LLY) Comparison side by side – The Financial Examiner

LLY

GW Pharmaceuticals plc (NASDAQ:GWPH) and Eli Lilly and Company (NYSE:LLY) compete with each other in the Drug Manufacturers – Major sector. We will analyze and contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation. Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of GW Pharmaceuticals plc and Eli Lilly and Company. GW Pharmaceuticals plc is better equipped to clear short and long-term obligations than Eli Lilly and Company.

Read Full Details

Story Sources

finexaminer.com
Topics:
  • Business
  • Health
  • Financial
News

Schizophrenia Drugs Market offers huge growth opportunities for the future; Eli Lilly and Company, Bristol-Myers Squibb – Honest Version

LLY BMY

Schizophrenia Drugs Market offers huge growth opportunities for the future; Eli Lilly and Company, Bristol-Myers Squibb. Get Sample Report Copy @https://www.crystalmarketresearch.com/report-sample/HC12414. The study of the Schizophrenia Drugs report is done based on the noteworthy research methodology that provides the analytical inspection of the global market based on various segments the market is divided into also the summary and latest size of the market owing to the various outlook possibilities. You not only get a look at the customized Schizophrenia Drugs industry segments according to geographical regions but also country or even different manufacturers in the market.

Read Full Details

Story Sources

honestversion.com
Topics:
  • Business
  • Financial
News

Antibiotics Market Competitive Analysis By 2026 : Pfizer, Janssen Pharmaceuticals, Abbott, GlaxoSmithKline, Sanofi, Novartis, Bayer, Bristol Myers Squibb Company, Eli Lilly and Company, Astellas Pharma - Wise Awareness

GSK SAN +5 more GSK SAN BAYN LLY PFE BMY GSK

Antibiotics Market Competitive Analysis By 2026 : Pfizer, Janssen Pharmaceuticals, Abbott, GlaxoSmithKline, Sanofi, Novartis, Bayer, Bristol Myers Squibb Company, Eli Lilly and Company, Astellas Pharma. Further, the Antibiotics Market report also reviews key players, major collaborations, merger & acquisitions along with trending innovation and business policies. With the help of market intelligence, our industry experts assess strategic options, outline successful action plans and aid companies make critical bottom-line decisions. All the stats, data, facts and figures collected to structure the Antibiotics market report are obtained from the trustworthy sources such as websites, journals, merges, newspapers and other authentic sources.

Read Full Details

Story Sources

wiseawareness.com
Topics:
  • Business
  • Financial
News

Global Insulin API Market 2019-2025: Novo Nordisk, Eli Lilly, Sanofi, Tong Hua Dong Bao Group – Buffalo Morning Star

SAN LLY

Global Insulin API Market 2019-2025: Novo Nordisk, Eli Lilly, Sanofi, Tong Hua Dong Bao Group. The report is designed to serve up-to-date information along with main statistics connected to the overall market and price forecast over a seven-year period, from 2019 to 2025. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds. A regional allotment is done to make the client a better understanding of the overall Insulin API market outlook at the macro and micro level. As mentioned about the regions, a comprehensive regional classification of the market is also added herein with their production, consumption, revenue, market share and progress rate, covering: North America, China, Europe, Southeast Asia, Japan, India.

Read Full Details

Topics:
  • Business
  • Financial
News

Know how C-X-C Chemokine Receptor Type 4 Market is Thriving by Top Players AdAlta Pty Ltd., Ambrx Inc., Anchor Therapeutics Inc., Biokine Therapeutics Ltd., BioLineRx Ltd., Bristol-Myers Squibb Company, Eli Lilly and Company, Globavir Biosciences Inc. - Industry Journal Pro

LLY BMY

Know how C-X-C Chemokine Receptor Type 4 Market is Thriving by Top Players AdAlta Pty Ltd., Ambrx Inc., Anchor Therapeutics Inc., Biokine Therapeutics Ltd., BioLineRx Ltd., Bristol-Myers Squibb Company, Eli Lilly and Company, Globavir Biosciences Inc. February 21, 2019. The report contains 103 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. The report contains basic, secondary and advanced information pertaining to the Scuba Diving Fins Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2018 – 2025.

Read Full Details

Topics:
  • Business
  • Financial